Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Core Business Performance - Day One Biopharmaceuticals reported a net product revenue of $38.5 million for OJEMDA in Q3 2025, marking a 15% increase from Q2 2025 and an 89% increase year-to-date compared to FY 2024 [7][13] - The total U.S. OJEMDA net product revenue for 2025 year-to-date reached $102.6 million [7] - Quarterly prescriptions (TRx) for OJEMDA grew to 1,256 in Q3 2025, representing an 18% increase compared to Q2 2025 [7] - New patient starts increased by 19% in Q3 2025, driven by data from the FIREFLY-1 clinical trial [7] Financial Highlights - The company raised its full-year 2025 net product revenue guidance for OJEMDA to between $145 million and $150 million, reflecting strong underlying demand [7] - Research and development expenses for Q3 2025 were $31.4 million, a decrease from $33.6 million in Q3 2024 [13] - Selling, general and administrative expenses were $28.1 million in Q3 2025, slightly down from $29.0 million in Q3 2024 [13] - The net loss for Q3 2025 was $19.7 million, compared to a net income of $37.0 million in Q3 2024 [13] Cash Position - As of September 30, 2025, the company had $451.6 million in cash, cash equivalents, and short-term investments [7][24] Corporate Developments - Heather Adkins Huet, PhD, joined Day One as Chief Scientific Officer in September 2025, bringing over two decades of experience in oncology therapeutics [5] - The company is progressing with the pivotal Phase 3 FIREFLY-2 clinical trial for first-line pediatric low-grade glioma (pLGG), with enrollment completion expected in the first half of 2026 [7] Upcoming Events - Three-year data from the FIREFLY-1 trial will be presented at the Society for Neuro-Oncology on November 23, 2025 [7]